

Alberta Drug Benefit List (ADBL) Interim Update now available online

Please be advised that the **March 1, 2023**, updates to the *Alberta Drug Benefit List (ADBL)* have been posted online at ab.bluecross.ca/dbl/publications.php.

Please refer to the March 1, 2023, updates for complete listings of products available by special authorization, step therapy/ special authorization, restricted benefit/special authorization, restricted benefits, added products, new established interchangeable groupings, least cost alternative price changes, products with a price change and discontinued products.

Please note that the online *interactive Drug Benefit List (iDBL)* at ab.bluecross.ca/dbl/idbl_main1.php is a near real-time application, and as such, contains the most up-to-date information.

Removal of temporary benefits from the *Alberta Drug Benefit List (ADBL)*

Due to the shortage of Gentamicin 40 mg/mL injection (DIN 02242652) manufactured by Sandoz Canada Inc., Gentamicin 40 mg/mL injection (DIN 02457008) manufactured by Hikma Pharmaceuticals PLC (Teligent Canada, Inc.) was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Sandoz Canada Inc. has advised Alberta Blue Cross® that the shortage for Gentamicin 40 mg/mL injection (DIN 02242652) has been resolved.

Gentamicin 40 mg/mL injection (DIN 02457008) will no longer be considered a temporary benefit for the *ADBL* after **March 9, 2023**. The above grouping was removed from the Critical Supply Product List **February 7, 2023**.

Due to the shortage of Vyvanse 30 mg Capsule (DIN 02322951) manufactured by Takeda Canada Inc., Vyvanse 10 mg Capsule (DIN 02439603) manufactured by Takeda Canada Inc. was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Takeda Canada Inc. has advised Alberta Blue Cross that the shortage for Vyvanse 30 mg Capsule (DIN 02322951) has been resolved.

Vyvanse 10 mg Capsule (DIN 02439603) will no longer be considered a temporary benefit for the *ADBL* after **February 7, 2023**. The above grouping was removed from the Critical Supply Product List **February 7, 2023**.

continued next page

continued from previous page

Due to the shortage of pms-Sulfasalazine 500 mg enteric-coated tablet (DIN 00598488) manufactured by Pharmascience Inc., Salazopyrin EN-Tabs 500 mg enteric-coated tablet (DIN 02064472) manufactured by Pfizer Canada ULC was added as a temporary benefit for the Alberta Drug Benefit List (ADBL).

Pharmascience Inc. has advised Alberta Blue Cross that the shortage for pms-Sulfasalazine 500 mg enteric-coated tablet (DIN 00598488) has been resolved.

Salazopyrin EN-Tabs 500 mg enteric-coated tablet (DIN 02064472) will no longer be considered a temporary benefit for the ADBL after March 13, 2023. The above grouping was removed from the Critical Supply Product List **February 10, 2023**.

Due to the shortage of Hydromorphone HP 10 mg/mL injection (DIN 02145928), manufactured by Sandoz Canada Inc., Hydromorphone HCL HP 10 mg/mL injection (DIN 02460610) manufactured by Sterimax Inc. was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Sandoz Canada Inc. has advised Alberta Blue Cross that the shortage for Hydromorphone HP 10 mg/mL injection (DIN 02145928) has been resolved.

Hydromorphone HCL HP 10 mg/mL injection (DIN 02460610) will no longer be considered a temporary benefit for the ADBL after **March 15, 2023**. The above grouping was removed from the Critical Supply Product List **February 13, 2023**.

Due to the shortage of Jamp-Quinine 300 mg capsule (DIN 02445204) manufactured by Jamp Pharma Corporation and Teva-Quinine 300 mg capsule (DIN 00021016) manufactured by Teva Canada Limited, Quinine-Odan 300 mg capsule (DIN 00695432) manufactured by Odan Laboratories Ltd. was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Teva Canada Limited has advised Alberta Blue Cross that the shortage for Teva-Quinine 300 mg capsule (DIN 00695432) has been resolved.

Quinine-Odan 300 mg capsule (DIN 00695432) will no longer be considered a temporary benefit for the ADBL after **March 21, 2023**. The above grouping was removed from the Critical Supply Product List **February 17, 2023**.

Temporary benefit added to the *Alberta Drug Benefit List (ADBL)*

Due to the unavailability of Teva-Cephalexin 125 25 mg/mL oral suspension (DIN 00342106) manufactured by Teva Canada Limited, Auro-Cephalexin 125 mg/ 5 mL oral suspension (DIN 02497743) and Auro-Cephalexin 250 mg/ 5 mL oral suspension (DIN 02497751) manufactured by Auro Pharma Inc. and Lupin-Cephalexin 50 mg/mL oral suspension (DIN 02469189) manufactured by Lupin Pharma Canada Limited will be considered as temporary benefits for the *Alberta Drug Benefit List (ADBL)*. These groupings were added to the Critical Supply Product List **February 14, 2023**.

As of **February 13, 2023**, all claims for **Auro-Cephalexin 125 mg/ 5mL oral suspension (DIN 02497743)**, **Auro-Cephalexin 250 mg/ 5 mL oral suspension (DIN 02497751)**, **Lupin-Cephalexin 50 mg/mL oral suspension (DIN 02469189)** and **Lupin-Cephalexin 25 mg/mL oral suspension (DIN 02469170)** will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice.

continued next page

continued from previous page

Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Sun Pharma Canada Inc. and Actavis Pharma Company that the shortage for Taro-Bupropion XL 150 mg extended-release tablet (DIN 02475804) and Teva-Bupropion XL 150 mg extended-release tablet (DIN 02439654) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **March 10, 2023**. The following grouping was removed from the Critical Supply Product List **February 8, 2023**.

BUPROPION HCL

150 MG EXTENDED-RELEASE TABLET

00002475804	TARO-BUPROPION XL	SGP	\$ 0.2926
00002439654	TEVA-BUPROPION XL	TEV	\$ 0.2926
00002275090	WELLBUTRIN X	VCL	\$ 0.5883

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

